Therapeutics News and Research

RSS

Mount Sinai venture to develop and scale distribution of COVID antibody test kits

Mount Sinai Health System ("Mount Sinai") and Renalytix AI today announced the formation of Kantaro Biosciences, LLC ("Kantaro"), a Mount Sinai venture, to develop and scale production and distribution of a test kit based on the Mount Sinai-developed high-performance serologic assay for SARS-CoV-2 antibodies.

20 May 2020

Researchers describe new methods to speed up drug approvals during pandemics

In response to the COVID-19 pandemic, researchers from the Massachusetts Institute of Technology have published a pair of studies in a COVID-19 special issue of the Harvard Data Science Review, freely available via open access, describing new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines and other anti-infective therapies.

20 May 2020

Phase IIB clinical trial initiated for treating hepatitis B-associated liver cancer

The first patients have been dosed in a multi-regional Phase IIB randomized, placebo-controlled clinical trial for the treatment of hepatitis B-associated liver cancer.

19 May 2020

Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins

Rentschler Biopharma SE, and Horizon Discovery, a leader in the application of gene editing, today announced the signing of a commercial license agreement.

From Revvity 19 May 2020

Study shows how normal RAS interacts with mutated RAS in living cells

Many cancer medications fail to effectively target the most commonly mutated cancer genes in humans, called RAS.

19 May 2020

New animal model for COVID-19

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to ravage the world, scientists are frantically searching for a vaccine or new drug that will effectively counter the lethal effects of the virus that leads to COVID-19 disease.

19 May 2020

Three FDA-approved drugs can block the replication of COVID-19 virus

Three drugs that are already approved by the Food and Drug Administration (FDA) or other international agencies can block the production of the novel coronavirus that causes COVID-19 in human cells, according to computational and pharmaceutical studies performed by UT Southwestern scientists.

19 May 2020

Global study to test whether antimalaria drug can prevent COVID-19 in health-care workers

With $9 million in philanthropic support, an international group of physicians and scientists is establishing a research network to evaluate promising therapies for COVID-19.

18 May 2020

Novel microRNA biomarker could help detect lymph node metastases in pancreatic cancer patients

For years, surgeons have operated on pancreatic cancer patients to remove what they thought was a localized tumor only to discover that the disease had spread to other, inoperable parts of the body. Now, a City of Hope molecular scientist thinks he may have found a way to prevent ineffective surgeries and prolong the lives of these patients.

18 May 2020

Novel insights on SARS-CoV-2 cell entry may inform further vaccine and treatment development

A research group from Harvard Medical School reported two cryo-electron microscopy structures derived from a single preparation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein in their paper available on the preprint server bioRxiv. Understanding the nuances of prefusion and postfusion conformations shed light on viral cell entry and may, in turn, guide the development of vaccines and drugs.

18 May 2020

Cross-neutralization of SARS and COVID-19 coronaviruses by a monoclonal antibody

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the cause of COVID-19.

18 May 2020

Boehringer Ingelheim acquires Northern Biologics to expand cancer immunology portfolio

Boehringer Ingelheim today announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies targeting the tumor microenvironment, Boehringer Ingelheim is now positioned at the forefront of the stromal biology space - an emerging area in cancer immunology.

From Boehringer Ingelheim International GmbH 18 May 2020

COVID-19 patients at high risk for developing complications associated with blood clots

When researchers from the University of Colorado Anschutz Medical Campus, Aurora, used a combination of two specific blood-clotting tests, they found critically ill patients infected with Coronavirus Disease 2019 (COVID-19) who were at high risk for developing renal failure, venous blood clots, and other complications associated with blood clots, such as stroke.

15 May 2020

Transition to virtual care during COVID-19 does not limit glycemic outcomes of diabetes inpatients

Ori Biotech and CellGenix to collaborate in order to promote innovation within closed-system cell and gene therapy manufacturing

Ori Biotech Ltd announced a partnership to achieve closed-system preparation and the addition of CellGenix media and growth factors within CGT manufacturing.

14 May 2020

Therapeutics News and Research

Mount Sinai venture to develop and scale distribution of COVID antibody test kits

Researchers describe new methods to speed up drug approvals during pandemics

Phase IIB clinical trial initiated for treating hepatitis B-associated liver cancer

Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins

Study shows how normal RAS interacts with mutated RAS in living cells

New animal model for COVID-19

Three FDA-approved drugs can block the replication of COVID-19 virus

Global study to test whether antimalaria drug can prevent COVID-19 in health-care workers

Novel microRNA biomarker could help detect lymph node metastases in pancreatic cancer patients

Novel insights on SARS-CoV-2 cell entry may inform further vaccine and treatment development

Cross-neutralization of SARS and COVID-19 coronaviruses by a monoclonal antibody

Boehringer Ingelheim acquires Northern Biologics to expand cancer immunology portfolio

COVID-19 patients at high risk for developing complications associated with blood clots

Transition to virtual care during COVID-19 does not limit glycemic outcomes of diabetes inpatients

University of Greenwich develops compounds that can fight COVID-19 killer

Boehringer Ingelheim partners with CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy

SCAI publishes position statement addressing optimal PCI treatment for complex CAD

NIH begins clinical study to evaluate hydroxychloroquine and azithromycin for COVID-19

Using supercomputers to screen drugs for deadly heart arrhythmias

Ori Biotech and CellGenix to collaborate in order to promote innovation within closed-system cell and gene therapy manufacturing

Advancing therapeutic biopolymer development eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News